Bosh sahifaNCYT • LON
add
Novacyt SA
Yopilish kursi
69,40 GBX
Yillik diapazon
39,07 GBX - 137,00 GBX
Bozor kapitalizatsiyasi
55,90 mln EUR
Oʻrtacha hajm
1,19 mln
Narx/foyda
-
Dividend daromadliligi
-
Asosiy maydon
EPA
Bozor yangiliklari
Moliyaviy axborot
Moliyaviy hisobot
Daromad
Sof foyda
(GBP) | dek, 2023info | Y/Y qiyosi |
---|---|---|
Daromad | 4,12 mln | 81,82% |
Joriy xarajat | 12,52 mln | 48,31% |
Sof foyda | -9,97 mln | -17,10% |
Sof foyda marjasi | -242,04 | 35,59% |
Har bir ulushga tushum | — | — |
EBITDA | -7,10 mln | -41,10% |
Amaldagi soliq stavkasi | 2,93% | — |
Balans
Jami aktivlari
Jami passivlari
(GBP) | dek, 2023info | Y/Y qiyosi |
---|---|---|
Naqd pul va qisqa investitsiyalar | 44,06 mln | -49,34% |
Jami aktivlari | 133,82 mln | -5,03% |
Jami passivlari | 46,57 mln | 81,32% |
Umumiy kapital | 87,24 mln | — |
Tarqatilgan aksiyalar | 70,63 mln | — |
Narxi/balansdagi bahosi | 0,56 | — |
Aktivlardan daromad | -21,46% | — |
Kapitaldan daromad | -28,44% | — |
Pul aylanmasi
Naqd pulning sof oʻzgarishi
(GBP) | dek, 2023info | Y/Y qiyosi |
---|---|---|
Sof foyda | -9,97 mln | -17,10% |
Operatsiyalardan naqd pul | -9,65 mln | -59,94% |
Sarmoyadan naqd pul | -7,47 mln | -3 853,70% |
Moliyadan naqd pul | -1,72 mln | -1 360,85% |
Naqd pulning sof oʻzgarishi | -18,84 mln | -197,44% |
Boʻsh pul | -3,81 mln | -56,02% |
Haqida
Novacyt Group is an Anglo-French biotechnology group focused on clinical diagnostics, with offices in Camberley, Surrey, United Kingdom and Vélizy-Villacoublay, France. The company produces in vitro and molecular diagnostic tests, supplying an extensive range assays and reagents worldwide. Its business units include Primerdesign, Microgen Bioproducts and Lab21 Healthcare.
In January 2020 the company announced that its molecular diagnostics division, Primerdesign, had launched a molecular test for the 2019 strain of SARSr-CoV. The test was approved as eligible for procurement under the World Health Organization's Emergency Use Listing process in April 2020, meaning that the test could be supplied by the United Nations and other procurement agencies supporting the COVID-19 response. In the same month Novacyt announced a collaboration with AstraZeneca, GlaxoSmithKline and the University of Cambridge to support the UK in its COVID-19 national screening programme at a new testing laboratory at the university's Anne McLaren laboratory. Wikipedia
Tashkil etilgan
2006
Sayt
Xodimlar soni
237